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Development of a tumor is a very complex process, and invasion and metastasis of malignant tumors are hallmarks
and are difficult problems to overcome. The tumor microenvironment plays an important role in controlling tumor fate
and autophagy induced by the tumor microenvironment is attracting more and more attention. Autophagy can be
induced by several stressors in the tumor microenvironment and autophagy modifies the tumor microenvironment,
too. Autophagy has dual roles in tumor growth. In this review, we discussed the interaction between autophagy and
the tumor microenvironment and the paradoxical roles of autophagy on tumor growth at different stages of tumor
development.
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Cancer cells are surrounded by a complex milieu. This
cancer cell niche is called the tumor microenvironment,
and it contributes to the development and metastasis of
tumors. The tumor microenvironment is a new emer-
ging concept in tumor research and has become a re-
search hallmark. The tumor microenvironment not only
contributes to cancer cell survival by supplying nutrients
but also contributes to tumor cell invasion and metasta-
sis. Thus, detecting the composition and function of the
tumor microenvironment is important for understanding
the mechanisms of tumorigenesis and tumor metastasis
to improve therapeutic strategies. The tumor micro-
environment is a complex system and is difficult to
study. It is composed of various stromal cells, including
fibroblasts, vascular endothelial cells, immune cells, adi-
pocytes, mesenchymal stems cells (MSCs), and various
cytokines [1]. The physiological characteristics of the
tumor microenvironment are clearly different from those* Correspondence: weilixin_smmu@163.com
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unless otherwise stated.of normal tissues and have been described as hypoxic,
nutrient deprived, energy limited, acidic, and inflamma-
tory [2-8]. These characteristics can induce autophagy
by activating various pathways [5-8]; thus, autophagy
can shape the tumor microenvironment. The crosstalk
between autophagy and the tumor microenvironment is
attracting increasing attention, as the tumor microenvir-
onment shaped by autophagy may play a crucial role in
modulating tumor development, metastasis, and thera-
peutic resistance.Tumor microenvironment-induced autophagy
Autophagy is an evolutionarily conserved catabolic path-
way from yeast to mammals that serves as a major lyso-
somal degradation pathway for recycling intracellular
components. Autophagy is emerging as the key process
that eliminates damaged macromolecules, including pro-
teins, lipids, and dysfunctional organelles. Autophagy is
a complex process comprising many steps (Figure 1), in-
cluding initiation, elongation, and autophagosome and
autolysosome formation. Macromolecules are targeted
to double-membrane vesicles called autophagosomes,
and autolysosomes form by fusion with lysosomes [9].
Cytoplasmic constituents are degraded and digested by
lysosomal enzymes in the autolysosome for recyclinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Process of autophagy. Autophagy includes five phases: initiation, elongation and autophagosome formation, fusion, and
autolysosome formation. Macromolecules are targeted to double-membrane vesicles called autophagosomes and then autolysosomes
form by fusion with lysosomes. Autophagy is initiated by the ULK1 complex containing ULK, Atg13, FIP200, and Atg101. Autophagosome
elongation and maturation involves two ubiquitin-like conjugation systems, such as the microtubule-associated protein 1 light chain 3 (LC3)
and the Atg12 systems. The autophagosome fuses with a lysosome to form an autolysosome, which degrades macromolecules into amino
acids, fatty acids, and nucleotides.
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acids, fatty acids, and nucleotides, are essential for cell
growth. The multi-step autophagic process is regulated
by a limited number of highly conserved genes known
as autophagy-related genes (ATGs) [10].
The formation of autophagosomes is initiated in mam-
malian cells primarily by the Unc51-like kinase 1 (ULK1)
complex containing ULK, Atg13, FIP200, and Atg101
[11-13]. Activation of this complex can be inhibited by
mammalian target of rapamycin (mTOR) complex 1,
which is a master negative regulator of autophagy in sev-
eral pathways [14,15]. Elongation and maturation of
autophagosomes involves two ubiquitin-like conjugation
systems, such as the microtubule-associated protein 1
light chain 3 (LC3) system and the Atg12 system [16].
Atg12 is conjugated to Atg5 by Atg7 (E1 enzyme) and
Atg10 (E2 enzyme). The Atg12-Atg5 heterodimer inter-
acts with Atg16L, and this complex promotes elongation
of the autophagic membrane [17]. LC3I is formed imme-
diately by Atg4B cleaving a free glycine residue after the
full-length LC3 precursor is translated. After autophagy is
induced, phosphatidylethanolamine (PE) is conjugated
with LC3I (called LC3II) by Atg7 (E1 enzyme) and Atg3
(E2 enzyme). PE-conjugated LC3 becomes an insoluble
form (LC3-II) that is stably inserted into the autophagoso-
mal membrane [18].
Autophagy occurs at a basal level in every cell as
housekeeping and plays key roles in cell development,immunity, tissue remodeling, and orientation with the sur-
rounding environment. In addition, in the tumor micro-
environment, autophagy is also activated in response to
multiple metabolic stressors (Figure 2a), such as oxygen/
nutrient deprivation, and degradation of the extracellular
matrix (ECM) [19,20].
Autophagy benefits cells suffering in an unfavorable
microenvironment by eliminating garbage and prevent-
ing accumulation of toxins. In contrast, autophagy also
supplies energy and compounds for cell survival and me-
tabolism. Thus, autophagy serves as an inherently cyto-
protective mechanism by self-eating [13].
Hypoxia and anoxia
The vasculature is insufficient to supply adequate oxy-
gen when solid tumor diameter is > 2 mm, resulting in
local hypoxic and anoxic conditions (oxygen concentra-
tions < 3% and < 0.1%, respectively) inside the tumor
[21]. Increasing evidence indicates that 50–60% of tu-
mors grow under hypoxic conditions [22-25], and that
enhanced autophagy promotes tumor cell survival [2].
Hypoxia within the immediate area of a tumor arises
mainly because the balance between oxygen consump-
tion and supply is disrupted. The supply of oxygen to
normal tissues and organs meets their metabolic re-
quirements, whereas oxygen consumption may outweigh
the insufficient supply to tumors, resulting in locally low
oxygen levels in tumor tissues. Hypoxia occurs in tumor
Figure 2 Paradoxical roles of autophagy induced by the tumor microenvironment during different stages of tumor development.
(a) Autophagy is induced by multiple stressors in the tumor microenvironment, including hypoxia, nutrient deprivation, inflammation, and ECM
detachment. Hypoxia activates autophagy through AMPK, PERK and HIF-1a/FOXO3 signaling pathways. The AMPK pathway is also activated by
nutrient deprivation. Autophagy can be also induced by ECM detachment through the Akt-mTORC1 and IKK pathways. Inflammation is another inducer
of autophagy that acts through the NF-κB signal pathway. (b) Before tumorigenesis, autophagy can suppress tumor initiation by protecting normal
cells and inhibiting inflammation (including inhibiting inflammasome and necrosis). In contrast, autophagy promotes tumor growth in established
tumors. Autophagy can promote inflammation by favouring inflammatory cells growth. Autophagy can also protect tumor cells and provide sufficient
oxygen and nutrient.
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sel structure and function, which is known as perfusion-
limited oxygen delivery, and exists transiently; (2) limited
oxygen diffusion due to increased transport distance
(>70 μm), which is called diffusion-limited oxygen deliv-
ery; and (3) impaired blood oxygen-carrying capacity in-
duced by tumor-associated or therapeutic-induced
anemia, which is termed anemic hypoxia [26].
Hypoxia-induced autophagy mainly depends on
hypoxia-inducible factors (HIFs), whereas anoxia-induced
autophagy is HIF independent [27,28]. HIFs are a family of
heterodimers containing a constitutive subunit and an
oxygen-regulated subunit that are only expressed when
oxygen concentration declines below a 5% threshold. HIF-
1α activates transcription of BNIP3 and BNIP3L (BNP3-
like protein, also known as NIX) under moderate hypoxia,
which disrupts the Beclin 1/Bcl-2 complex, releasing
Beclin1 and activating autophagy [28-31], as Beclin1 is an
autophagy-activator gene. Moreover, transcription of
BNIP3 and BNIP3L is upregulated by the FOXO3 tran-
scription factor. Mammucar et al. showed that FOXO3
overexpression upregulates LC3 expression and increases
LC3 lipidation in skeletal muscle cells, resulting in activa-
tion of autophagy [32]. FOXO3 also plays a key role in ac-
tivating hematopoietic stem cells under nutrient-deprived
conditions [33]. BNIP3L, which is often present on the
outer mitochondrial membrane, modulates elimination
of mitochondria by autophagy (mitophagy). HIF-2 also
regulates autophagy in chondrocytes and surprisingly
inhibits HIF-1α function [34]. Other pathways involvedin hypoxia-induced autophagy include the protein DJ-1
pathway (also called CAP1/RS/PARK7), the platelet-
derived growth factor receptor-dependent pathway, and
the unfolded protein response (always elicited by endo-
plasmic reticulum stress) [28,35-37]. Furthermore, inhi-
biting mTOR and stimulating of 5′ AMP-activated
protein kinase (AMPK) contribute to inducing autoph-
agy. Hypoxia-induced autophagy also requires eIF2α
phosphorylation mediated by PERK to reach the max-
imum level [38]. Hypoxia increases transcription of the
essential autophagy genes LC3 and Atg5 by activating
the transcription factors ATF4 and CHOP, respectively,
both of which are regulated by PERK [38].
Nutrient deprivation
Proliferating cancer cells must sustain intracellular energy
and nutrient levels to survive, but essential ingredients in
the microenvironment at the early stage of tumorigenesis
are insufficient for cancer cell survival [39]. Thus, cancer
cells are nutrient deprived and to survive must cope with
this stress using available metabolic pathways. Nutrient (in-
cluding amino acids and glucose) depletion is the most po-
tent physiological inducer of autophagy. Several studies
have shown that autophagy plays a critical role in protect-
ing cells against nutrient depletion [40,41]. Ammonia, gen-
erated from deamination of glutamine in mitochondria,
stimulates autophagic flux in an autocrine and/or paracrine
manner [42]. Amino acids, particularly branched-chain
amino acids, activate mTORC1 and inhibit autophagy.
Thus, the absence of amino acids induces autophagy by
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cells require sufficient ATP supplied by glucose, so a lack
of glucose will activate autophagy to sustain energy
homeostasis [44]. In addition, glucose deprivation may in-
duce autophagy by oxidative stress [45]. Moreover, recep-
tor for advanced glycation end product (RAGE) activates
autophagy by inhibiting mTOR and blocks apoptosis in
pancreatic cancer cells, which increases their survival [46].
Another report demonstrated that autophagosomes form
in colorectal cancer cells under amino acid- and glucose-
deprived conditions, which may contribute to survival of
the cancer cells [39].
Autophagy can also be stimulated by activating the
AMPK pathway to protect cancer cells against nutrient
starvation. AMPK holds the core node that integrates
several autophagy-inducing stimuli. The AMP: ATP ra-
tio is a key factor for AMPK to monitor energy. Several
upstream AMPK kinases, including liver kinase B1 (acti-
vated by energy depletion), calcium/calmodulin kinase
kinase-ß (activated by cytosolic Ca2+), and transforming
growth factor (TGF)-ß-activated kinase-1 (involved in
activating IKK) activate AMPK by phosphorylating a
threonine residue on its catalytic α-subunit [47]. The best-
studied mechanisms by which AMPK induces autophagy
are inhibiting mTORC1, phosphorylating tuberous scler-
osis complex 2, and regulating the mTOR-associated pro-
tein, Raptor. mTOR can also be inhibited by a growth
factor deficiency, such as insulin and insulin-like growth
factor [21].
Inflammation
Inflammation is a cellular response that occurs at cell and
tissue injury sites. Tumors were described as unhealed
wounds by Dvorak over 20 years ago and were believed to
produce inflammatory mediators, such as cytokines and
chemokines, continuously. Tumor progression is accom-
panied by increased expression of inflammation-associated
genes [48]. It has been widely accepted that chronic inflam-
mation promotes cell malignancy and tumorigenesis. Bulk
inflammatory cytokines, such as tumor necrosis factor
(TNF)-α, interleukin (IL)-6, TGF-β, and IL-10, contribute
to the occurrence and development of cancer. In 1863,
Rudolf Virchow proposed that inflammation plays a key
role in tumor progression. He found that inflammatory
cells infiltrate tumors [49]. His hypothesis was proved by
recent studies that infection and chronic inflammation-
associated disease can drive cancers [50].
The initial goal of inflammation is to eradicate foreign
bodies and tumors [51]. Tumor tissues not only stimu-
late an adaptive immune response by recruiting T lym-
phocytes, dendritic cells (DC), and occasional B cells but
also mediate the innate immune response by recruiting
macrophages, polymorphonuclear leucocytes, and rare
natural killer cells. However, if the inflammation cannotbe controlled, surrounding tissues may be subjected to
malignant transformation. Cytokines in the tumor micro-
environment regulate the anti-tumor response, but cyto-
kines induce cancer in another way during chronic
inflammation [52]. Inflammation increases the risk of
tumorigenesis due to the bioactive molecules secreted by
cells that have infiltrated the tumor milieu, including cyto-
kines, growth factors, and chemokines that maintain cell
growth, limit apoptosis, and promote angiogenesis [53].
Furthermore, inflammation can activate autophagy [54].
Tumor cells induce oxidative stress in adjacent fibro-
blasts; thus, inducing nuclear factor kappa B (NF-κB) and
activating HIF-1α, which stimulate autophagy [55-57].
Furthermore, NF-κB is a key regulator of the inflammatory
response, suggesting a close connection between inflam-
mation and autophagy. Ubaldo et al. showed that co-
culturing fibroblasts with tumor cells activates the NF-κB
signaling pathway and induces a cytokine storm that in-
cludes IL-6, IL-8, IL-10, macrophage inflammatory protein
1-α, interferon-γ, RANTES, and granulocyte-macrophage
colony-stimulating factor. Treatment with these cytokines
can drive autophagy [58]. Thus, it has been speculated that
inflammation plays a positive role in the occurrence of
autophagy.
Detachment of the ECM
The attachment of epithelial cells to the ECM is medi-
ated by integrin and is vital for cell growth and survival
[59]. Loss of ECM attachment leads to a type of apop-
tosis known as anoikis [60]. Some studies have shown
that a lack of appropriate ECM contact also robustly in-
duces autophagy to promote cell survival, either during
early formation of carcinoma or in the later stages of
dissemination and metastasis [61,62]. Moreover, compo-
nents of the ECM regulate autophagy and mitigate its
role in cell survival, and adhesion of HeLa cells to colla-
gen I or IV is one of the mechanisms [63]. Another
study of MCF10A mammary epithelial cells (MECs) in
a three-dimensional culture system showed that au-
tophagy is rapidly induced to enhance cell survival
during anoikis when cells are grown under low ECM
attachment conditions [64]. Depletion of human
ATGs, such as ATG5, ATG6 and ATG7, by si-RNA in-
hibits matrix detachment-induced autophagy [65].
Chen et al. reported that the phosphatidylinositol-3-
kinase (PI3K)-AKT-mTORC1 pathway is a major regula-
tor of autophagy in detached mouse fibroblasts. Activation
of the PI3K-AKT-mTORC1 pathway decreases during
ECM detachment, which is correlated with the activation
of autophagy. Activation of the IKK complex plays a key
role promoting autophagy in MECs deprived of ECM con-
tact [66]. Thus, both the PI3K-AKT-mTORC1 and IKK
pathways are important regulators of autophagy during
ECM detachment.
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As described before, multiple stressors drive autophagy
in the tumor microenvironment, and increasing evidence
shows that autophagy modifies the tumor microenviron-
ment through different pathways. [13]. Autophagy is a
key lysosomal pathway that degrades macromolecules,
including intracellular organelles, denatured proteins,
and nucleic acids and contributes to cell reconstruction,
regeneration, and repair by recycling and reusing cellular
contents. In the tumor microenvironment, autophagy
may display different properties.
Autophagy promotes angiogenesis
Autophagy has important roles in tumor angiogenesis.
Autophagy-associated genes in endothelial cells, such as
Atg5, modulate starvation and hypoxia-evoked angio-
genesis, which may occur through the high mobility
group box 1 (HMGB1) pathway [67]. HMGB1 is a major
chromatin-associated protein that translocates to the
cytoplasm and is released from endothelial cells under
stress [68]. HMGB 1 is released by damaged or dead
cells and acts as an inflammatory cytokine and damage-
related protein. In addition, extracellular HMGB 1 elicits
autophagy by binding to Beclin 1 [69]. HMGB 1 is an
important effector of the crosstalk between endothelial
cells and tumor cells and favors angiogenesis and tumor
cell survival in a hypoxic microenvironment.
Autophagy supplies nutrients
Normal fibroblasts adjacent to tumor cells undergo re-
programming during tumor development by interacting
with tumor cells. Fibroblasts acquire the myofibroblast
phenotype and are known as cancer-associated fibro-
blasts (CAFs). Lisanti et al. revealed that heightened au-
tophagy in CAFs plays a key role in energy support for
neighboring epithelial tumor cells and favors their survival
[70]. When CAFs overexpressing pro-autophagic mole-
cules were co-injected with cancer cells into immunocom-
promised mice, they promoted tumor growth and lung
metastasis. In contrast, activating autophagy in cancer
cells reduces tumor growth [71]. This result suggests that
CAFs supply sufficient energy for tumor cell growth by
generating a fertile stroma and nutrients and that autoph-
agy plays different roles in various compartments [72].
However, it remains unclear how the paradoxical roles of
autophagy in tumors are regulated. Increasing evidence in-
dicates that the role of autophagy in tumors is far more
complex than thought previously [13].
Suppressing autophagy in apoptosis-deficient tumor
cells impairs their survival under stress conditions
in vivo and in vitro, indicating that autophagy sustains
cell survival when nutrients are limited [2]. Cells undergo-
ing autophagy provide nutrition by degrading intracellular
proteins and organelles. Autophagy ensures metabolism ofhematopoietic stem cells during trophic factor deprivation
[73]. Moreover, autophagy sustains nutrient metabolism
when nutrient levels are low during mouse development
[74]. All of these results show that autophagy favors cell
metabolism and energy balance. In contrast, defects in au-
tophagy increase the incidence of many cancers, such as
human breast, ovarian, and prostate cancers [75-77].
Autophagy regulates the inflammatory response
Growing evidence in the last 10 years suggests that in-
flammation plays a key role in tumor occurrence and de-
velopment. Autophagy has been also proposed to be a
key regulator of inflammation through various mecha-
nisms, as an autophagy deficiency increases necrosis and
inflammation in tumor cells, whereas activating autoph-
agy has the opposite effect. White’s team demonstrated
in 2006 that impaired apoptosis and autophagy induces
necrosis; thus, stimulating the inflammatory response
and accelerating tumor growth [21]. All of these results
indicate that autophagy plays a key role in cell death and
inflammation induced by necrosis.
Unlike cell apoptosis, necrosis provokes an inflamma-
tory storm. HMGB1 released from necrotic cells acti-
vates NF-κB after binding to the cell surface receptor
RAGE [78,79]. Nucleic acids from necrotic cells elicit in-
flammation through a Toll-like receptor. Several studies
have shown that autophagy blocks two forms of necrotic
cell death, such as necroptosis and poly-ADP-ribose
polymerase (PARP)-mediated cell death. Necroptosis is
dependent on caspase and induced by a cell death lig-
and, such as TNF-α and FasL. PARP-mediated cell death
is another form of programmed-necrotic cell death that
can be induced by DNA damage [80,81]. In contrast,
inhibiting the autophagy-related genes Atg5 and Beclin
1 results in increased sensitivity of cells to necrotic death
[82] IL-1α released from necrotic cells activates Kupffer
cells, which produce cytokines, induce TNF-α, IL-6, and
hepatocyte growth factor and activate NF-κB, leading to
hepatocarcinogenesis [83]. Massey et al. showed that a
deficiency in Atg16L1 is involved in Crohn’s disease,
suggesting a potential role of autophagy in promoting
inflammation [84]. Autophagy regulates inflammatory
signals directly. Inflammasomes can activate under
autophagy-deficient conditions and promote maturation
of inflammatory cytokines including IL-1β and IL-18
[85]. Further studies showed that mitochondrial reactive
oxygen species (mtROS) produced by damaged mito-
chondria play a crucial role in this process. ROS activate
the NLRP3 inflammasome, which promotes caspase 1
maturation. Activated caspase 1 cleaves pro-IL-1β to
produce matures IL-1β that is subsequently secreted by
cells [86]. In addition, mtROS also act as signaling mole-
cules to trigger other inflammatory cytokines, such as
TNF-α and IL-6 [87]. Furthermore, autophagy affects
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cells migrating to a tumor inflammatory site, promote in-
flammation and activate macrophages and DCs [88]. The
activation of autophagy in neutrophils mediates death of
neutrophils, which results in decreased inflammation [89].
In contrast, antigen-presenting cells (APCs), such as mac-
rophages and DCs, undergo autophagy to survive under
stress conditions [90].
Autophagy stimulates the innate and adaptive immune
responses. Autophagy is involved in activating DCs
[91,92]. Autophagy in T cells has also been investigated.
Autophagy is activated in both CD4+ and CD8+ T cells to
promote their proliferation [93,94]. CD4+ and CD8+ cells
deficient in ATG3, ATG5 and ATG7 cannot proliferate
after they are activated [95,96], and Atg5−/− lymphocytes
fail to repopulate the periphery due to overwhelming cell
death [93]. Autophagy in APCs and T cells promotes the
inflammatory response.
Paradoxical roles of autophagy during different
stages of tumor development
Tumor microenvironment-driven autophagy have differ-
ent roles in different stages of tumor development
[2,3,97] (Figure 2b), the mechanism of which remains
unclear. There has been work suggesting that autophagy
is activated in different cells during different stages of
tumor development, thus results in different effects on
tumor growth.
Autophagy inhibits early tumorigenesis
Autophagy was initially considered to be a process that
suppressed malignant transformation. The first direct
evidence of the relationship between autophagy and can-
cer was established in 1999, when Levine et al. discov-
ered that Beclin1 is a candidate tumor suppressor gene
[77]. They found that Beclin1 is monoallelically deleted
in a high percentage of human breast and ovarian can-
cers, and that Beclin1 expression is frequently low in hu-
man breast cancer, including cell lines and cancer
tissues. Moreover, increased Beclin1 expression in breast
cancer cell lines inhibits cell proliferation in vitro and
tumor generation in nude mice [77]. Then, the importance
of single copy loss of the Beclin1 gene was exhibited in
Beclin1 heterozygous knockout mice, which are prone to
develop spontaneous lymphomas, lung cancers, and liver
cancers, as well as accelerated hepatitis B virus-induced
hepatocarcinogenesis [75]. Levine et al. further found that
Akt suppresses autophagy by mTOR-independent phos-
phorylation of Beclin1 and ultimately promotes tumori-
genesis [98].
Many other autophagy machinery components besides
Beclin1 play tumor-suppressive roles in tumorigenesis.
Atg4C knockout mice have increased susceptibility to
develop carcinogen-induced fibrosarcomas [99]. UVradiation resistance associated gene and Bif-1, which are
components of the Beclin1/class III PI3K complex, also
participate in controlling cell proliferation and suppressing
tumorigenesis [100,101]. Notably, Atg5 mosaic-deleted
mice develop spontaneous benign liver tumors, but no tu-
mors are detected in other organs. Liver-specific deletion
of Atg7 also leads to benign liver tumors in a mice model
[102]. Atg5 −/− or Atg7−/− mice or mice hypomorphic
for Atg16L1 exhibit intestinal Paneth cell abnormalities re-
sembling Crohn’s disease, which may results in intestine
cancer [103,104]. Atg4, Atg 5, Atg 12 and Atg 9b have also
been demonstrated to be deleted or mutated in various
human cancers [7]. These reports suggest that tumor sup-
pression may be a property of the autophagy machinery
but is not associated with a signal autophagy protein. Tu-
mors in both studies were benign hepatic adenomas but
not frank cancer, suggesting that loss of autophagy may be
a trigger for primary tumorigenesis, but not for malignant
progression during late tumorigenesis.
Autophagy promotes established tumor growth
In addition to tumor suppression role of autophagy in the
initial process of tumorigenesis, autophagy seemingly plays
an opposite role as a tumor promoter in established can-
cers. Several studies have shown that autophagy promotes
survival of tumor cells under several stressors [21]. Degen-
hardt et al. showed that activation of autophagy in evolving
tumors promotes tumor survival [2]. Another study by Sun
suggested that autophagy suppresses hepatocarcinogenesis
during the dysplastic stage and promotes hepatocarcino-
genesis at the tumor-forming stage [105]. Except for the
difference in tumor type, this strange phenomenon may re-
sult from differences in the incipient cells involved with
tumor development. Altman et al. found that a deficiency
of autophagy following deletion of Atg3 aggravates BCR-
Abl-expressing hematopoietic precursor cell death under
stress and prevents BCR-Abl-mediated leukemogenesis
[106]. White’s group also found that Ras expression upre-
gulates basal autophagy, which was required for survival of
immortal mouse kidney epithelial cells during starvation
and during Ras-mediated tumorigenesis [107]. A study in a
conditional FIP200-knockout mouse model showed that
inhibiting autophagy retards MMTV-PyMT-mediated
tumorigenesis of mammary epithelial cells by impairing
tumor cell survival and proliferation [108].
The process of tumorigenesis involves activation of vari-
ous oncogenes and inactivation of anti-oncogenes. Autoph-
agy may mainly impact tumor cells and consequently play
a role as a tumor promoter during oncogene-mediated
tumor development. However, it appears that the protu-
morigenic role of autophagy extends beyond the hypoxia/
nutrient deprived regions of a tumor. Detachment of the
ECM during early carcinoma formation or in the later
stages of dissemination and metastasis robustly induces
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ates therapeutic resistance in a variety of situations [97].
Tumor cells can survive after chemo- or irradiation ther-
apy by activating autophagy. Li et al. showed that inhibit-
ing autophagy with 3-methyladenine or by targeting Atg7
enhances the 5-fluorouracil treatment effect in human
colorectal cancer cells [109]. Inhibiting autophagy also
enhances the therapeutic efficacy of cisplatin and 5-
fluorouracil in esophageal and colon cancer cells, respect-
ively [109,110]. The autophagy inhibitor chloroquine (CQ)
and hydroxychloroquine (HCQ) have been used to en-
hance the anti-tumor effects of toxic drugs in clinical tri-
als. Furthermore, autophagy may be a key modulator of
tumor metastasis [111] by regulating the epithelial-
mesenchymal transition, which can be induced in the
tumor microenvironment.
Autophagy has different roles in different cells
Normal cells
Normal cells face the unfavourable microenvironment and
are involved in metabolic stress in early stage of tumorigen-
esis. Metabolic stressors distinctly impact on cellular gen-
ome stability. Metabolic stressors disturb the mechanisms
of DNA synthesis/repair by accumulating misfolded and
aggregate-prone proteins, and reactive oxygen species
(ROS)-generating organelles, especially mitochondria. In
autophagy-competent cells, autophagy clears these accu-
mulations to limit the metabolic stress. In contrast, autoph-
agy defection sensitizes normal cells to metabolic stress,
and results in DNA damage increase, gene amplification
and aneuploidy increase, and ultimately promotes tumori-
genesis [3,112]. These data showed that autophagy plays
an important role in the protection of genomic stability in
normal cells and inhibiting tumorigenesis. In addition, au-
tophagy deficiency leads to differentiation disorder and ab-
normal proliferation of stem cells, both of which may be
the early events in the process of tumorigenesis [113,114].Figure 3 Concise summary of relation between autophagy and tumo
in the tumor microenvironment including hypoxia, nutrient deprivation, inf
different cells at different stages of tumor growth and have paradoxical rol
normal cells survival and suppresses tumorigenesis. In contrast, after tumor
promotes tumor growth.Cancer cells
It has been known that autophagy not only benefits nor-
mal cells suffering from metabolic stress, but also pro-
tects cancer cells in the stress microenvironment during
tumor development. In the rapidly growing stage of
tumor development, angiogenesis can not satisfy the
great demand of amino acids, oxygen and growth factors
for fast-proliferating tumor cells. Autophagy can digest
damaged proteins, organelles and other macromolecules
and recycle cytoplasmic materials to balance the demand
of nutrients and energy [115]. And a series of metabolic
stressors (including starvation, hypoxia, and ROS accu-
mulation) induce autophagy for survival in tumor cells
[116]. In addition to metabolic stress-activated autoph-
agy, autonomous autophagy also plays a crucial role in
tumor development. Recently, many studies have shown
that several types of tumor cells require autonomous au-
tophagy for tumor growth in normal condition [107,117].Tumor-associated mesenchymal stem cells
In tumors, there are various cell types constituting the
tumor stroma [13]. Mesenchymal stem cells is an im-
portant component of tumor stroma and have multiple
roles in the tumor microenvironment [118]. The effect
of MSCs on tumor cells in stressful conditions has also
been described. MSCs promote survival and drug resist-
ance in various hematological tumors [119-121]. Recent
studies have established that MSCs provide sufficient
stromal support for tumor cells [122]. The effect of
MSCs on tumor growth in the tumor microenvironment
may be related to activating autophagy. Cecilia et al.
demonstrated that serum-deprived MSCs (SD-MSCs)
express Beclin1, ATG10, and ATG12 and the SD-MSCs
undergoing autophagy provide the needed nutrients and
secrete survival and anti-apoptotic factors for self-
survival and survival of surrounding cells [123].r growth. Autophagy can be induced by different metabolic stressors
lammation and ECM detachment. Autophagy can be activated in
es in tumor growth. Before tumorigenesis, autophagy promotes
igenesis, autophagy promotes survival of the cancer cells and thus
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Tumor microenvironment is very important to tumor
growth, metastasis and therapy resistance and attracts
more and more attention. Studies have shown that au-
tophagy is an important factor in the tumor microenvir-
onment. The mechanism of autophagy interfaced with
tumor microenvironment still remains unclear and
needs to be explored. But previous studies suggested
that autophagy is not only a result of the tumor micro-
environment, but also has effect on it. The tumor micro-
environment can activate autophagy through different
pathways and autophagy can modify the tumor micro-
environment by promoting angiogenesis, supplying nu-
trients, and modulating the inflammatory response and
thus help the cells in the tumor microenvironment over-
come metabolic stress, maintain homeostasis, and sur-
vive in poor microenvironment.
Tumor resistance to radiotherapy and chemotherapy is
also associated with autophagy. Various tumor-associated
animal models have confirmed that autophagy inhibition
has the effects of enhancing chemosensitivity and promot-
ing tumor regression. Of the known autophagy inhibitors,
only CQ/HCQ have been evaluated in human clinical tri-
als [124].There have been more than 50 clinical trials
working on CQ/HCQ efficacy in various human cancers,
particularly in advanced or metastatic cancers (https://
clinicaltrials.gov). A combination of an autophagy inhibi-
tor with a toxic drug possibly is an alternative treatment
for advanced or metastatic cancer, and HCQ may be pre-
ferred to CQ due to its more acceptable side effects [125].
However, autophagy-targeted therapy still should be cau-
tious because autophagy has dual roles in tumor growth
progress (Figure 3). The dual roles of autophagy in tumor
growth may be tissue-dependent and vary among different
stages of tumor growth. Thus, autophagy inhibitor may
play different roles in different stages and types of tumor
growth. In addition, excess and sustained autophagy leads
to tumor cell death or senescence, which results in tumor
dormancy. Therefore, using autophagy as a tumor treat-
ment target should be further investigated and studying
autophagy in tumor microenvironment is very important
for discovery of new therapeutic targets.Abbreviations
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